在评估疫苗接种与治疗时对SARS-CoV-2变异株JN.1活病毒微量中和试验的准确评价
本研究比较了Omicron亚变异株JN.1在Vero V1与Caco-2细胞中的培养方法,发现Vero V1培养导致低滴度或Spike弗林蛋白酶切割位点关键突变,而Caco-2细胞可产生序列纯净的毒株。使用Caco-2培养的毒株评估71名英国健康成人接种第五剂加强针后的中和抗体滴度,结果显示接种前两组针对JN.1的中和抗体滴度相当(p=0.240),接种后单价XBB.1.5疫苗组的中和抗体滴度较BA.4/5二价疫苗组高2.6倍(p<0.001)。在临床相关浓度下,治疗性单克隆抗体Sotrovimab对JN.1的中和活性仅边际维持。
要点
- JN.1在Vero V1细胞中培养导致低滴度或Spike弗林蛋白酶切割位点关键突变。
- 接种后单价XBB.1.5疫苗组针对JN.1的中和抗体滴度较BA.4/5二价疫苗组高2.6倍(p<0.001)。
- 在临床相关浓度下,Sotrovimab对JN.1的中和活性仅边际维持。
核心结论
- 使用Caco-2细胞培养可获得序列纯净的JN.1毒株用于准确评估中和抗体滴度。
- 接种后单价XBB.1.5疫苗诱导的针对JN.1的中和抗体滴度高于BA.4/5二价疫苗。
- 在临床相关浓度下,Sotrovimab对JN.1的中和活性仅边际维持。
研究设计与样本
- 研究比较了JN.1在Vero V1细胞与Caco-2细胞中的培养方法,并评估了71名英国健康成人接种第五剂COVID-19疫苗加强针后的血清中和抗体滴度。
主要发现
- 所有参与者在接种前均可检测到针对JN.1的中和抗体,两组基线中和抗体滴度相当(p=0.240)。
- 接种后,单价XBB.1.5疫苗组针对JN.1的中和抗体滴度较BA.4/5二价疫苗组高2.6倍(p<0.001)。
- 在临床相关浓度下,Sotrovimab对JN.1的中和活性仅边际维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging SARS-CoV-2 variants require rapid assessments of pathogenicity and evasion of existing immunity to inform policy. A crucial component of these assessments is accurate estimation of serum neutralising antibody titres using cultured live virus isolates. Here, we report a comparison of culture methods for Omicron sub-variant JN.1 and the subsequent evaluation of neutralising antibody titres (nAbTs) in recipients of BNT162b2-XBB.1.5 monovalent and the ancestral/BA.4/5 containing bivalent vaccines. We compared culture of JN.1 in either Vero V1 cells or Caco-2 cells, finding culture in Vero V1 either resulted in low-titre stocks or induced crucial mutations at the Spike furin cleavage site (FCS). Using sequence-clean culture stocks generated in Caco-2 cells, we assessed serum samples from 71 healthy adults eligible for a COVID-19 vaccination given as a 5th dose booster in the UK: all participants had detectable nAbs against JN.1 prior to vaccination, with baseline/pre-existing nAbTs between both vaccine groups comparable (p = 0.240). However, nAbTs against JN.1 post-vaccination were 2.6-fold higher for recipients of the monovalent XBB.1.5 vaccine than the BA.4/5 bivalent vaccine (p < 0.001). Further, at clinically relevant concentrations the therapeutic monoclonal antibody Sotrovimab marginally maintains neutralisation of JN.1. Regular re-appraisal of methods and policy outcomes as new variants arise is required to ensure robust data are used to underpin future severity assessments and vaccine strain selection decisions.
引用
- Dowgier G, Hobbs A, Greenwood D, et al. Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics. Vaccine. 2025. PMID: 40056806. doi:10.1016/j.vaccine.2025.126960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。